How to Help Your Patients Save Money on Lynparza: A Provider's Guide to Savings Programs

For oncology providers, the prescription is only part of the work. Ensuring your patients can actually afford Lynparza (olaparib) is just as important—especially given its retail price of approximately $17,000–$20,000 per month. Without proactive financial counseling and enrollment in assistance programs, cost-related non-adherence is a real clinical risk.

This guide is designed to give oncology practices a complete reference for Lynparza savings programs in 2026—from manufacturer copay cards to Medicare assistance to independent foundations.

The Cost Reality: Why Financial Counseling Is Clinical

Research consistently shows that financial toxicity leads to medication non-adherence in cancer patients. For Lynparza, the consequences of skipped doses or treatment discontinuation extend beyond quality of life—they may affect disease outcomes in a patient population already managing serious cancer.

Oncology practices that proactively address the financial component of treatment—at the time of prescribing, not after—are better positioned to maintain patient adherence throughout the course of Lynparza therapy. Integrating financial navigation into the prescribing workflow is not just a patient service; it's a clinical best practice.

Program 1: Lynparza Co-pay Savings Program (AstraZeneca)

The Lynparza Co-pay Savings Program is AstraZeneca's primary financial assistance vehicle for commercially insured patients.

Savings: Eligible patients pay as little as $0/month; program maximum savings up to $26,000/year

Eligibility: Commercially insured patients with a valid Lynparza prescription; no income requirements

Ineligible: Medicare Part B/D, Medicaid, TRICARE, VA, Department of Defense beneficiaries

How to enroll: Via Access 360 at 1-844-275-2360, at the specialty pharmacy, or at myaccess360.com

Coverage: Covers drug cost only; does not cover office visits or associated medical costs

Best practice: Enroll commercially insured patients at the time of prescribing, before the first specialty pharmacy fill. Early enrollment prevents cost-related delays at the pharmacy counter.

Program 2: AZ&Me Prescription Savings Program

For patients who are uninsured or whose insurance does not adequately cover Lynparza, the AZ&Me Prescription Savings Program provides the medication at no cost to qualifying patients.

Benefit: Free Lynparza for qualifying patients; 90-day supply, shipped to patient or prescriber every quarter

Eligibility: Income-based; uninsured or underinsured patients residing in the U.S.; annual enrollment

Medicare note: Medicare patients enrolled in the Low Income Subsidy (LIS/Extra Help) may be eligible; those in non-LIS Medicare are generally not eligible

Contact: 1-800-AZandMe (1-800-292-6363) or azpatientsupport.com

Program 3: Medicare and Government-Insured Patient Strategies

Medicare patients present unique challenges because they are excluded from manufacturer copay programs. Key strategies for Medicare patients:

$2,000 OOP Cap (2025+): Medicare Part D now caps annual out-of-pocket drug costs at $2,000/year—a significant protection for specialty drug patients.

Medicare Prescription Payment Plan: Allows patients to spread OOP costs evenly across the year rather than paying large amounts early. Available starting January 2025.

Low Income Subsidy (Extra Help): Identifies Medicare patients who qualify for substantial drug cost subsidies. Refer eligible patients to Social Security Administration for LIS application.

AZ&Me for qualifying Medicare patients: LIS-enrolled Medicare patients may qualify for AZ&Me assistance in addition to their Part D benefit.

Program 4: Independent Patient Assistance Foundations

Independent foundations are particularly important for Medicare patients not eligible for manufacturer programs. Fund availability changes regularly—check current open enrollment before referring patients:

Patient Advocate Foundation (PAF) — patientadvocate.org; copay assistance and case management

CancerCare Co-payment Assistance Foundation — cancercare.org; cancer-specific financial assistance

HealthWell Foundation — healthwellfoundation.org; disease-specific copay and premium funds

Ovarian Cancer Research Alliance (OCRA) — ocrahope.org; financial assistance for ovarian cancer patients

Triage Cancer — triagecancer.org; resource navigation for cancer patients

Building a Financial Navigation Workflow into Your Practice

To proactively address Lynparza affordability for every patient, consider implementing these workflow steps:

At prescribing: Identify insurance type (commercial vs. Medicare/Medicaid) and route to the appropriate assistance program.

For commercial: Enroll immediately in the Lynparza Co-pay Savings Program via Access 360 (1-844-275-2360).

For uninsured/underinsured: Apply for AZ&Me (1-800-292-6363) and begin the intake process.

For Medicare: Assess LIS eligibility, explain the $2,000 OOP cap, and refer to relevant independent foundations.

At follow-up visits: Proactively ask about adherence and any cost-related barriers. Document and address them.

How medfinder Supports Your Patients' Access Journey

Once your patients are enrolled in a savings program and have a prescription ready, they still need to locate a specialty pharmacy that can fill Lynparza. medfinder for providers can help identify which specialty pharmacies in your patient's area have Lynparza in stock—eliminating another barrier in the access chain.

For guidance on the full spectrum of Lynparza access issues beyond cost, see: How to Help Your Patients Find Lynparza In Stock: A Provider's Guide.